Evidence map›Paper›PMID 39199635›Full record

ArticleCancers2024

Real-Life Management of FLT3-Mutated AML: Single-Centre Experience over 24 Years.

Saveria Capria, Silvia Maria Trisolini, Lorenzo Torrieri, Elena Amabile, Giovanni Marsili, Alfonso Piciocchi, Walter Barberi, Anna Paola Iori, Daniela Diverio, Daniela Carmini and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Observational
  2. Leukemia cutis as the first manifestation of acute myeloid leukemia.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Saveria CapriaHematology AOU Policlinico Umberto I, 00161 Rome, Italy.
Silvia Maria TrisoliniHematology AOU Policlinico Umberto I, 00161 Rome, Italy.
Lorenzo TorrieriHematology, Department of Translational and Precision Medicine, "Sapienza" University, 00185 Rome, Italy.
Elena AmabileHematology, Department of Translational and Precision Medicine, "Sapienza" University, 00185 Rome, Italy.ORCID 0009-0002-0511-3656
Giovanni MarsiliGIMEMA Foundation, 00182 Rome, Italy.ORCID 0009-0003-1231-1770
Alfonso PiciocchiGIMEMA Foundation, 00182 Rome, Italy.ORCID 0000-0001-8648-885X
Walter BarberiHematology AOU Policlinico Umberto I, 00161 Rome, Italy.
Anna Paola IoriHematology AOU Policlinico Umberto I, 00161 Rome, Italy.
Daniela DiverioHematology AOU Policlinico Umberto I, 00161 Rome, Italy.
Daniela CarminiHematology AOU Policlinico Umberto I, 00161 Rome, Italy.
Massimo BrecciaHematology, Department of Translational and Precision Medicine, "Sapienza" University, 00185 Rome, Italy.ORCID 0000-0003-1163-6162
Maurizio MartelliHematology, Department of Translational and Precision Medicine, "Sapienza" University, 00185 Rome, Italy.
Clara MinottiHematology AOU Policlinico Umberto I, 00161 Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We analyzed 140 patients with a median age of 51 years; 21% had WBC ≥ 100 × 10

Indexed as

acute myeloid leukemia (AML)chemotherapycomplete remission (CR)FLT3 mutationshematopoietic stem cell transplantation (HSCT)long-term outcomesmidostaurinminimal residual disease (MRD)relapsetyrosine kinase inhibitors (TKIs)

Identifiers

PMID39199635
PMCPMC11352495

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.